CLL Prognostication/Risk Stratification Gene Panel near me in Warangal

Name: Book CLL Prognostication/Risk Stratification Gene Panel Test in Warangal - Best Price & Home Sample Collection
Brand: Tata 1mg
SKU: CLL Prognostication/Risk Stratification Gene Panel
Price: 19950 INR
Availability: InStock

Also referred as

Chronic Lymphocytic Leukaemia Genetic Testing

For men & women

Earliest reports in

19 days

Contains

1 test

Test price:

₹19950

~~₹21000~~

5% off

Know when you'll get your report

For sample collection between

Reporting in

19 days

You can select your preferred slot on cart

Know more about this test

The CLL Prognostication/Risk Stratification Gene Panel is an advanced genetic test used to assess disease prognosis in Chronic Lymphocytic Leukemia (CLL). It detects specific gene mutations associated with disease progression, treatment response, and overall outcome, helping doctors make informed, personalized treatment decisions. By identifying these genetic changes, the test helps stratify patients into low-, intermediate-, or high-risk categories and guides the selection of the most appropriate management approach, including active surveillance, targeted therapy, or clinical trial options. This test is widely available with Tata 1mg labs at an affordable price in Warangal.

Samples required

Blood

Find out

Why is this test booked?

Preparation for this test

Sample Collection

Who will collect your samples?

What does CLL Prognostication/Risk Stratification Gene Panel measure?

The CLL Prognostication/Risk Stratification Gene Panel analyzes multiple genes in the blood that are linked to the development and progression of Chronic Lymphocytic Leukemia (CLL). It uses advanced PCR-based next-generation sequencing (NGS) to detect genetic mutations and variations that help predict how aggressive the disease might be and how it may respond to treatment.

This panel includes:

Hotspot genes (ABL1, FLT3, JAK2, MYD88, SF3B1): Common regions where mutations often occur in blood cancers.

Full genes (SH2B3, TP53): Entire genes analyzed to identify both common and rare mutations that influence prognosis and therapy response.

Gene fusions (FGFR1, FGFR2, PDGFRA, PDGFRB): Abnormal joining of genes that may drive cancer growth and affect targeted treatment choices.

By studying these genes, the test helps determine disease prognosis, identify high-risk patients, and guide doctors in planning personalized treatment strategies and follow-up care.

Test Information is reviewed by: Dr. Swati Gupta (Anand), MD Lab Medicine, MBBS and written by Shweta Prakash, MSc, BSc . The test details are for information purpose only. Consult a doctor before taking any test. Last updated on: 30th Oct 2026

Did you find information useful ?